ABBOTT PARK, Ill., MALVERN, PA & TOKYO, JAPAN, Feb. 12, 2024 – Abbott and Fujirebio announced today a partnership to develop a research use only (RUO) neurofilament-light chain (Nf-L) neurology biomarker assay for use on Abbott’s Alinity® i. Abbott will make the RUO assay available to researchers conducting studies demonstrating the utility of the Nf-L biomarker. Research with the Nf-L biomarker is ongoing in a variety of neurological diseases including multiple sclerosis, Alzheimer’s, traumatic brain injury and cognitive impairment. Abbott and Fujirebio are seeking to make the Nf-L research use only assay for Abbott’s Alinity i available by 2025.
